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Toxoplasmosis and its control 
[s2081 Toxoplasmosis in the immunocompromised 
patient 
J.S. Ilciiiingon', M.A. Krupp'. 'Division of Infections Diseases and 
Geosrupliic Medicine, Stanfbrd University Srliool of Medicine, 
'Departnierzt of Immuiiolo~y and lnf ict ious Diseases, Research Institute, 
Palo Alto Medical Foundation, Palo A h ,  CA, USA 
Toxoplasma p n d i i  is among the most common causes of latent 
infection of humans throughout the world. This chronic latent 
infection is associated with cysts of the organism in multiple organs 
and appears to be an active process of cyst disruption and reformation, 
ordinarily unaccompanied by clinical evidence of disease or tissue 
destruction. Immunologically normal individuals with acute acquired 
toxoplasma infection usually have a self-limited clinical course and 
do not require specific treatment directed at the parasite. Both 
humoral and cell-mediated immunity mediate the resistance, 
although the latter appears to play the primary role. Limitation of 
spread and containment of the latent form of the infection is 
compromised when there is a severe defect in the immune system 
and especially in cell-mediated immunity. This is most clearly 
evidenced by the tragic and frequent occurrence of toxoplasinosis in 
individuals with the acquired immunodeficiency syndrome (AIDS), 
The mechanisms by which infection with Exoplasma i s  maintained 
in a quiescent state are incompletely understood. The advent ofAIDS 
and its associated immunologic abnormalities has revealed how 
important a severe disturbance ofT-lymphocyte function is as a factor 
predisposing to developinent of toxoplacniosis in the imniuno- 
compromised host. This i s ,  at least in part, due to an abnormality in 
production of cytokines critical to resistance against this organism. 
Although this has received widespread atteiitioii in the literature, the 
subject of toxoplasmosis in patients who are iiniiiunocompromised 
by other conditions has been relatively neglected in the literature. 
Toxoplasmosis has been found to be associated with a wide variety 
of conditions that result in immunosuppression and has been reported 
to involve nearly every organ system in AIDS and non-AIDS 
imniunoconipromised patients. Clinical syndromes associated with 
toxoplasmosis in iinniunocomproiiiised patients are most frequently 
encephalitis, myocarditis, and pneunionitis. In addition, cases of 
widely disseminated toxoplasnia infection have been described. The 
majority of cases in non-AIDS imrnunocompromised patients have 
occurred in individuals with malignancies, most frequently 
Hodgkin's lymphoma, and in recipients of heart, bone marrow and 
renal transplants. Clearly, toxoplasmosis can be present in the 
iiiiiiiunosuppressed patient without malignancies, including those on 
corticosteroids or with systemic lupus erythematosus. Thus, patients 
on iminunosuppressive regimens niay be seriously predisposed to 
developinent of toxoplasniosis. The unusual occurrence, protean 
clinical manifestations, and devastating consequences of toxo- 
plasniosis in the imniunoconipromised host emphasize the need for 
clinical acunien in the diaposis, management and prevention of this 
disorder. 
Treatment of Toxoplasma infection in pregnant 
women and newborns 
regimens have been used throughout Europe for nearly 30 years. 
Spiraniycin and high-dosc pyriniethamine combined with 
sulfadiazine-folinic acid (P-S-F) have been the d r u g  of choice for 
primary infection in pregnancy, Both regimens have been shown to 
eradicate parasites from infected placentas, while P-S-F has also led 
to a reduction in clinical symptoms of infected infants. 
In a recent multicenter European study a comparison was made 
between 144 seroconverting mothers of whom 119 received prenatal 
treatment, and 125 mothers who were not treated at all. The anti- 
parasitic treatment given in pregnancy had no inipact on the vertical 
transmission rate, but was significantly beneficial in regard to coiii- 
plications of infected infants (OR=0.30) and especially for the 
absence of severe sequelae at 1 year of age (OK=0.14, 95% CI: 
As for postnatal treatment, trials from the USA using continuously 
high doses of P-S-F for a year in symptomatic infants showed a 
striking effect on the ophthalmologic and nephrologic outconie and 
development. In soine countries in Europe, low-dose pyrimethamine 
combined with sulfadoxine (Fansidar) has been used both during 
pregnancy of infected inothers and during the first years of infccted 
infants, yielding a good preventive effect. In future, the new drug  
azithroniycin and ataquovone, which may influence the cystic stage, 
niay prove to be effective. A recent trial of azithroinycin in pregnant 
women will be reported. 
0.04-0.58). 
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Adeno-associated virus vectors for gene 
therapy 
R. Heilbronn, C. Schetter, A. Krahn, S. Weger. liistitirte cf Ittfictioirs 
Diseases, Department cf Virolq)), Free Uniuersity qf Berlin, Berlin, 
Germany 
Viral vectors based on human adeno-associated virus (AAV) have 
become of increasing interest for gene therapy due to several 
advantages over coiiipeting viral vector systems. AAV is non-patho- 
genic, non-immunogenic and infects virtually every cell type tested 
so far, including terminally differentiated or non-dividing cells, 
where the introduced transgene is highly and stably expressed for 
many months. These features have made AAV the preferred vector 
system for applications where stable long-term expression in a 
quiescent cell pool is required and nonspecific iminune stimulation 
should be avoided. 
Unfortunately, AAV vector preparation is very tedious and labonr- 
intensive due to an obligatory DNA transfection step for every round 
of AAV vector production. We have designed a new system for the 
production of rAAV by constructing a helper virus which expresses 
all required AAV helper functions in a single recombinant herpes- 
virus. As a consequence, packaging of rAAV i s  no longer dependent 
on DNA transfection efficiencies but rather relies on simple infection 
of cells to deliver the necessary components. Details of this new 
method for rAAV production will be presented. Use of the strategy 
appears to be a promising step towards large-scale production of 
recombinant AAV vectors to high titers by serial infections. This will 
open the possibility of preparing the enormous vector quantities 
required for clinical applications. 
B. Stray-Pedersen. Gynecolosy/~bs~etr irs  Departmcwr, Natiorial 
Hospital, University of Oslo, Oslo, Norway 
Primary maternal toxoplasina infection can cause congenital 
infection with unpredictable severe sequelae. Different treatment 
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Is2121 Recombinant bacterial vaccine carriers 
C. Locht. INSERM U447, lnsfitut Pasteur de Lille, Lille, France 
Objectives: Mucosal infections often induce better and longer- 
lasting protection than parented vaccination. Therefore, several 
attenuated bacterial live vectors have been developed, mostly adapted 
for the gastrointestinal tract. However, oral vaccination has several 
disadvantages that may perhaps be overcome by intranasal adminis- 
tration. We have therefore developed an attenuated live Bordetella 
pertussis vector specifically adapted for intranasal immunization. 
Methods: The gene coding for pertussis toxin, the major 
virulence factor of B. pertussis, was deleted from the chromosome by 
homologous recombination. Heterologous antigens were fused to the 
filamentous hemagglutinin, the major secreted protein of the 
organism, through the construction of chimeric genes. Mice were 
then infected with the recombinant attenuated or non-attenuated 
strains, and colonization as well as immunogenicity were measured. 
The mice were then challenged with either virulent B. pertussis or 
the microorganisms corresponding to the heterologous antigens, and 
protection was evaluated. 
Results: The deletion of the pertussis toxin gene did not 
dramatically alter colonization. The attenuated strains were at least as 
immunogenic as the non-attenuated strains, and a single intranasal 
administration of an attenuated recombinant strain was able to protect 
against both B. pertussis and heterologous challenges. 
Conclusions: Recombinant attenuated B. pertussis can be used to 
protect against B. pertnssis and heterologous challenges after a single 
intranasal immunization. 
Vaccination against stomach ulcers caused by 
Helicobacter pylori 
R. Rappuoli. IRIS, Chirofi S.p.A., Siena, Italy 
Helicobacterpylori is a ‘slow’ bacterial pathogen that affects about 50% 
of the population in developed countries and about 80% of the 
population in the developing world. The most common pathology 
associated with H .  pylori infection is chronic active gastritis and peptic 
ulceration, although long-term chronic infection is a risk factor for 
gastric adenocarcinoma and lymphoma. While infection is usually 
acquired early in life, only decades later does severe pathology appear. 
During these long periods of incubation, the host mounts a vigorous 
immune response against H .  pylori which fails to resolve the infection 
and may contribute to the severity of the disease. Evidence has 
accumulated indicating a role for a polarized T-helper 1 cell response 
in the gastric pathology induced by H .  pylori. Furthermore, a 
pathogenicity island in type 1 H .  pylori strains has been shown to be 
responsible for H .  pylori-induced inflammation. 
H .  pylori infection is currently treated with an association of anti- 
secretory drugs and antibiotics. However, recent advances in animal 
models have provided the rationale for the entry into human clinical 
trials of an H .  pylori vaccine. The challenge of the coming years will 
be to identify a vaccine formulation to be tested in clinical trials and 
to identify the target population of a candidate H .  pylori vaccine, as 
well as to test the efficacy of therapeutic immunization. 
Data on the progress of vaccine development will be presented. 
Progress of vaccine adoption into national 
immunizations programs 
M. Miller. Children’s Vaccine Initiative, Geneva, Switzerland 
Introduction: Governments are increasingly faced with complicated 
policy choices regarding vaccine use, as indicated by the slow uptake 
of ‘new’ vaccines. 
Methods: We have compiled country-specific databases of 
epidemiologic and economic data for vaccine-preventable disease to 
allow national governments to assess the required financial resources 
and benefits of prevention through vaccination programs for measles, 
hepatitis B (HB), Haemophilus injuenzae type B (Ha) and rotavirus. 
The cost-effectiveness of various vaccines for each country and 
predictors of vaccine uptake were estimated. 
Results: Although new vaccines cost more than traditional 
vaccines, in most countries they would be considered cost-effective 
based on costing less than per capita gross domestic product (GDP) 
per year of life saved. However, financial constraints limit their use. 
Countries where the HB vaccine cost was <0.5% of GDP and where 
routine coverage with DPT was >80% are 6.5 and 3.5 times more 
likely, respectively, to have adopted HB vaccine than countries which 
do not meet these criteria. Disease burden estimates represented a 
relatively low predictor for uptake. 
Conclusions: Quantitative analysis of the health benefits and 
economic implications of vaccination options can help the policy- 
making process and may encourage the appropriate allocation of 
financial resources to fund cost-effective vaccination programs. 
New opportunities to improve outcomes in 
community RTls 
[ E l  A new fluoroquinolone and opportunities to 
improve infection management with 
quinolones 
L. Mandell. Henderson General Hospital, McMaster Medical Unit, 
Hamilton, ON, Canada 
The treatment of patients with lower respiratory tract infections 
(LRTIs), such as acute and chronic bronchitis, acute exacerbations of 
chronic bronchitis and, in particular, community-acquired pneu- 
monia (CAP), is a complex and difficult area. A variety of factors 
make treatment decisions difficult, and physicians must often resort 
to empirical therapy. CAP is not a homogeneous entity; a variety of 
pathogens may be responsible, dependmg upon the patient’s age, the 
presence of co-morbid illnesses, where the infection was acquired, 
and the severity of the illness. Complicating matters further are the 
increase in resistance among various pathogens, particularly Strepto- 
coccuspneumoniae, the growing awareness of the importance of atypical 
pathogens, and the possibility of co-infection. The site of care 
decision is also very important and affects both the types of drugs that 
can be used and the overall costs associated with treatment. Approxi- 
mately 80% of CAP patients may be treated outside the hospital with 
mortality rates of less than 1%; those requiring hospital admission 
have substantially higher mortality rates. Current diagnostic methods 
rely on either the clinical approach or the use of invasive techniques. 
The former relies upon information obtained 6om patient history, 
physical examination and chest X-ray; the latter is dependent upon 
methods such as fiberoptic bronchoscopy. Both have limitations. 
Given these problems, it is clear that empirical therapy is usually 
required. The new fluoroquinolone, trovafloxacin, provides coverage 
against the pathogens of concern, while, at the same time, exhibiting 
